Non Small Cell Lung Cancer, Small-cell Lung Cancer
Conditions
Keywords
Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Immunotherapy, Progression free Survival, Survival
Brief summary
Observational, prospective clinical research, multi-center clinical research platform with the main objective to assess molecular biomarker testing, treatment and outcome of patients with NSCLC or SCLC in Turkey
Detailed description
In Turkey, non-small cell lung cancer (NSCLC) is the most common cause of cancer-related death in men and one of the most common causes of cancer-related deaths in women. Because of the heterogeneity of NSCLC or SCLC, it is crucial to characterize the biology of the tumor as exact as possible, to predict the course of disease as accurate as possible, and to determine the optimal therapeutic algorithm as early as possible after initial diagnostic work-up. These efforts are an obligatory part of the initial diagnostics, since thorough knowledge of the biology of the disease and the resulting therapeutic options ensure optimal care of Volunteers with NSCLC or SCLC. The aim of REGISTURK is to set up a national clinical research platform to document molecular testing, treatment and course of disease of patients with NSCLC or SCLC.
Interventions
None listed
Sponsors
Mahmut Gumus
Study design
Observational model
OTHER
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Patient histopathologically diagnosed with non-small cell lung cancer or small cell lung cancer 2. Written informed consent no later than six weeks after start of first-line treatment 3. Age ≥ 18 years
Exclusion criteria
* Volunteers participating in a research program for non-small cell or small cell lung cancer that includes interventions outside of routine clinical trial
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Frequency of molecular/mutational analysis | throughout of treatment, 36 months | To collect data on the frequency of molecular/mutational biomarker testing |
| Type of molecular/mutational analysis | throughout of treatment, 36 months | To collect data on the type of molecular/mutational biomarker testing |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Progression free survival time | throughout of treatment, 36 months | Progression free survival |
| Overall survival time | throughout of treatment, 36 months | Overall survival |
| Type of treatment | throughout of treatment, 36 months | To describe systemic treatments and sequential treatments applied in real-life practice. |
| Advers events rate | throughout of treatment, 36 months | Advers events |
| The frequency of comorbidities | throughout of treatment, 36 months | Comorbidities rate |
| The Rate of Response Rate | throughout of treatment, 36 months | Response rate |
Countries
Turkey (Türkiye)
Outcome results
None listed